Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients
Por:
Masana, L, Correig, E, Rodriguez-Borjabad, C, Anoro, E, Arroyo, JA, Jerico, C, Pedragosa, A, la Miret, M, Naf, S, Pardo, A, Perea, V, Perez-Bernalte, R, Plana, N, Ramirez-Montesinos, R, Royuela, M, Soler, C, Urquizu-Padilla, M, Zamora, A, Pedro-Botet, J
Publicada:
16 feb 2022
Resumen:
Aim Assessing the effect of statin therapy (ST) at hospital admission for COVID-19 on in-hospital mortality. Methods and results Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk. Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients [1234 men, 923 women; age: 67 y/o (IQR 54-78)] admitted to the hospital were retrieved from the clinical records in anonymized manner. Three hundred and fifty-three deaths occurred. Five hundred and eighty-one patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on ST than the matched non-statin group (19.8% vs. 25.4%, chi(2) with Yates continuity correction: P = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared with the GM non-statin group (17.4%; P = 0.045). The Cox model applied to the CSH function [HR = 0.58(CI: 0.39-0.89); P = 0.01] and the competing-risks FG model [HR = 0.60 (CI: 0.39-0.92); P = 0.02] suggest that statins are associated with reduced COVID-19-related mortality. Conclusions A lower SARS-CoV-2 infection-related mortality was observed in patients treated with ST prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19.
Filiaciones:
Masana, L:
Univ Rovira & Virgili, Univ Hosp St Joan IISPV, LIPIDCAS, CIBERDEM, Reus, Spain
Correig, E:
Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Stat Dept, Reus, Spain
Rodriguez-Borjabad, C:
Univ Rovira & Virgili, Univ Hosp St Joan IISPV, LIPIDCAS, CIBERDEM, Reus, Spain
Anoro, E:
Pius Hosp Valls, LIPIDCAS, Valls, Spain
Arroyo, JA:
Barcelona Autonomous Univ, Univ Hosp Santa Creu & St Pau, Lipid Unit, Barcelona, Spain
Jerico, C:
Hosp Moises Broggi, Lipid Unit, Consorci Sanitari Integral, St Joan Despi, Spain
Pedragosa, A:
Consorci Sanitari Terrassa, Lipid Unit, Terrassa, Spain
la Miret, M:
Hosp Verge Cinta, Endocrinol Dept, LIPIDCAS, Tortosa, Spain
Naf, S:
Univ Rovira & Virgili, Univ Hosp Joan XXIII, Endocrinol Dept, CIBERDEM,LIPIDCAS,IISPV, Tarragona, Spain
Pardo, A:
Hosp Delfos, Internal Med Dept, Barcelona, Spain
Perea, V:
Hosp Mutua Terrasa, Lipid Unit, Barcelona, Spain
Perez-Bernalte, R:
Hosp Vendrell, LIPIDCAS, El Vendrell, Spain
Plana, N:
Univ Rovira & Virgili, Univ Hosp St Joan IISPV, LIPIDCAS, CIBERDEM, Reus, Spain
Ramirez-Montesinos, R:
Hosp St Pau & Santa Tecla, LIPIDCAS, Tarragona, Spain
Royuela, M:
Xarxa Assistencial Univ Manresa, Lipid Unit, ALTHAIA, Barcelona, Spain
Soler, C:
Hosp Santa Caterina, Lipid Unit, Girona, Spain
Urquizu-Padilla, M:
Barcelona Autonomous Univ, Univ Hosp Vall Hebron, Lipid Unit, Barcelona, Spain
Zamora, A:
Hosp Blanes, Lipid Unit, Corporacio Salut Maresme & Selva, Blanes, Spain
Pedro-Botet, J:
Barcelona Autonomous Univ, Univ Hosp Mar, Lipid Unit, Barcelona, Spain
Bronze, Green Accepted, Green Published
|